Abstract: The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combination with other therapeutic agents.

Abstract: A portable electronic lock comprises a lock body and a securing part that is movable relative to the lock body between a closed position and an open position, wherein the lock body comprises an electromechanical locking device that has an electric motor having a rotor, a latch coupled to the rotor, and a control circuit. The latch can be electrically driven by means of the electric motor from a locking position, in which the securing part located in the closed position is locked to the lock body, into an unlocking position in which the securing part is released for a movement into the open position. A mechanical driving of the latch can be effected by a moving of the securing part from the open position into the closed position, with the latch being drive-effectively coupled to the rotor of the electric motor such that the mechanical driving of the latch effects a forced rotational movement of the rotor. The control circuit is configured to detect the forced rotational movement of the rotor.

Abstract: The present invention relates to novel conjugates comprising a targeting moiety linked to a phosphoantigen moiety, and the use thereof in the treatment of diseases, such as cancer, infectious diseases and autoimmune diseases, optionally in combination with other therapeutic agents. A targeting moiety may be an antibody, or binding fragment thereof. The phosphoantigen may be a prodrug. The invention further relates to linker-drug compounds comprising a phosphoantigen moiety, for use in the manufacture of conjugates, and pharmaceutical compositions comprising said immunoconjugates.

Abstract: The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combination with other therapeutic agents.

Abstract: The present invention relates to binding agents of human Leucine-rich Repeat Kinase 2 (LRRK2). More particular, allosteric modulators of LRRK2 activity have been identified, for targeting LRRK2 in human cells, while leaving LRRK2 subcellular localisation unaffected. Even more specifically, protein binding agents for allosteric modulation of LRRK2 kinase activity are disclosed, comprising immunoglobulin single variable domains (ISVDs) binding to human LRRK2 with nanomolar affinity. The invention thus reveals means and methods for a novel LRRK2 targeting approach through allosteric modulation of its activity for use in treatment of LRRK2-related pathologies, such as Parkinson's disease, as well as for use in detection of LRRK2 in vitro and in vivo, and for use as a diagnostic.

Abstract: The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combination with other therapeutic agents.

Abstract: The present invention relates to the recruiting of patients for one or more medicament studies. The subjects of the present invention are a method, a system and a computer program product for recruiting patients for one or more medicament studies with the aid of an individual identification feature that is applied to the packaging of a medicament.

Abstract: A system, a method and a computer program product for automated detection and recognition of adverse events for monitoring the state of health of an individual

Abstract: This disclosure describes a method for preparing stable cell targeting conjugates. A further aspect of this disclosure relates to the stable cell targeting conjugates obtainable by the method and to pharmaceutical compositions comprising these stable cell targeting conjugates. A last aspect of this disclosure relates to the use of these conjugates and pharmaceutical compositions as a medicament.

Abstract: A first aspect of the disclosure relates to a method for preparing cell-targeting conjugates by coupling at least one functional moiety, such as a therapeutic compound, diagnostic compound or chelating agent to a targeting moiety. A second aspect of this disclosure relates to the cell-targeting conjugates obtainable with this method. A third aspect of the disclosure described herein relates to pharmaceutical compositions comprising the cell-targeting conjugates.

Abstract: Cell targeting conjugates that comprise a targeting moiety and one or more functional moieties bound thereto via a linker, wherein the linker comprises a transition metal complex and wherein at least 90% of the conjugates have a ratio of functional moieties to targeting moieties (DAR) of or less. A pharmaceutical composition comprising the cell targeting conjugates and the use of the conjugates and composition as a medicament, in particular, in the treatment of cancer.

Abstract: Method for operating a network having a prescribable topology, wherein the topology contains a plurality of network devices which are connected to one another and interchange data via multiwire data lines connected to their data ports, wherein test messages are also sent to the data lines in order to check whether or not two data ports on two network devices have the connection between them via the interposed data line, characterized in that, in a prescribable time interval, the number of CRC errors which have occurred and the number of data items transmitted in this time interval are ascertained on a data line between two data ports, and at least these two values are used to calculate an error rate which is a measure of the operability of the multiwire data line.

Abstract: The present invention discloses a closed system for thermochemical storage comprising at least one water condenser and at least two thermochemical modules, wherein a first thermochemical module comprises a first thermochemical material and a second thermochemical module comprises a second thermochemical material, and wherein the at least one water condenser and the thermochemical modules are connected so that water vapor can be exchanged individually between any two selected from the list consisting of the at least one water condenser and the at least two thermochemical modules. A method for desorption in the system according to the invention is also described. In this method, the first thermochemical module is used as a condenser to dry the second thermochemical module.

Abstract: A documentation file is received that includes a plurality of sections and user system parameter data is accessed that identifies attributes of a computing system of a particular user. A subset of the plurality of sections are determined to be presented to the particular user based on the attributes of the computing system and a value for inclusion in content of a particular one of the subset of sections is determined based on the attributes. A customized version of the documentation file is presented on a display device that includes the particular section, omits sections in the plurality of sections outside the subset of sections, and includes the value in presentation of the particular section.

Abstract: A documentation file is received that includes a plurality of sections and user system parameter data is accessed that identifies attributes of a computing system of a particular user. A subset of the plurality of sections are determined to be presented to the particular user based on the attributes of the computing system and a value for inclusion in content of a particular one of the subset of sections is determined based on the attributes. A customized version of the documentation file is presented on a display device that includes the particular section, omits sections in the plurality of sections outside the subset of sections, and includes the value in presentation of the particular section.

Abstract: This disclosure describes a method for preparing stable cell targeting conjugates. A further aspect of this disclosure relates to the stable cell targeting conjugates obtainable by the method and to pharmaceutical compositions comprising these stable cell targeting conjugates. A last aspect of this disclosure relates to the use of these conjugates and pharmaceutical compositions as a medicament.

Abstract: The present invention discloses a closed system for thermochemical storage comprising at least one water condenser and at least two thermochemical modules, wherein a first thermochemical module comprises a first thermochemical material and a second thermochemical module comprises a second thermochemical material, and wherein the at least one water condenser and the thermochemical modules are connected so that water vapour can be exchanged individually between any two selected from the list consisting of the at least one water condenser and the at least two thermochemical modules. A method for desorption in the system according to the invention is also described. In this method, the first thermochemical module is used as a condenser to dry the second thermochemical module.

Abstract: Method for operating a network having a prescribable topology, wherein the topology contains a plurality of network devices which are connected to one another and interchange data via multiwire data lines connected to their data ports, wherein test messages are also sent to the data lines in order to check whether or not two data ports on two network devices have the connection between them via the interposed data line, characterized in that, in a prescribable time interval, the number of cyclic redundancy check (CRC) errors which have occurred and the number of data items transmitted in this time interval are ascertained on a data line between two data ports, and at least these two values are used to calculate an error rate which is a measure of the operability of the multiwire data line.

Abstract: A light source (7) with a gas-discharge lamp includes a control module (16) with a driver circuit, an ignition module (17) for producing a substantially high voltage, and a gas-filled burner (18) in which an electric arc is ignited and maintained between two electrodes (19, 20). The control module (16), ignition module (17), and burner (18) are attached to a mutual support system (21) and combined in a single unit. Lighting equipment (1) for a motor vehicle includes at least one light source (7).